ml-3000 has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brewer, M; Cruz-Monserrate, Z; Houchen, CW; Janakiram, NB; Kumar, G; Lightfoot, S; Madka, V; May, R; Mohammed, A; Patlolla, JM; Rao, CV; Ritchie, RL; Sadeghi, M; Steele, VE; Yamada, HY | 1 |
| Biddick, L; Brewer, M; Devarkonda, V; Janakiram, NB; Lightfoot, S; Madka, V; Mohammed, A; Rao, CV; Steele, VE | 1 |
2 other study(ies) available for ml-3000 and Pancreatic Neoplasms
| Article | Year |
|---|---|
Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Arachidonic Acid; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Proliferation; Ceruletide; Cyclooxygenase 2; Disease Models, Animal; Disease Progression; Doublecortin-Like Kinases; Lipoxygenase Inhibitors; Mice; Mice, Knockout; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Pancreatitis; Protein Serine-Threonine Kinases; Pyrroles | 2015 |
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Carcinoma, Pancreatic Ductal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; ErbB Receptors; Female; Gefitinib; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Signal Transduction | 2015 |